“Four vaccines developed by Chinese companies have moved on to Phase 3 trials, accounting for half of the global candidates at that final stage of human testing before approval.”
Read the full article @ SupChina:
Month: September 2020
UBS Mulls China Expansion, New Hires for Asset Management | Bloomberg
“UBS Group AG is exploring options to expand its asset-management business in China, taking advantage of relaxed rules to defend its leading position among foreign players in the 100 trillion yuan ($14.8 trillion) market.
Under new regulations introduced this year, foreign firms such as UBS can take full control of their mutual fund joint ventures in China, or seek partnerships with a local bank’s asset management arm to increase offerings.
“We’re not ruling out any opportunities,” Raymond Yin, head of Asia Pacific for UBS Asset Management said in an interview from his base in Shanghai, without specifying any plans. “We will continue to invest in the China market to maintain our leadership position.””
Read the full article @ Bloomberg:
Sino-Swiss migration deal sparks controversy | swissinfo.ch
“Elected officials and NGOs have raised concerns about an accord between Bern and Beijing that allows Chinese agents to visit Switzerland to identify and deport illegal residents. Defenders of the agreement argue it is a mechanism that facilitates the application of the law.”
Read the full article @ swissinfo.ch:
China’s belt and road: from Malaysia to Philippines, Asean projects face roadblocks | SCMP
“Chinese firms have since 2013 signed deals with Asean nations to build projects such as railways, bridges, dams and special economic zones.
But many have been slow to start, with negotiations over loan amounts, environmental concerns and corruption causing years-long delays.”
Read the full article @ SCMP (paywall):
China’s CNBG, Sinovac find more countries to test coronavirus vaccines | Reuters
“China National Biotec Group (CNBG) and Sinovac Biotech Ltd said on Saturday they have each found two more countries to run late-stage clinical tests of their coronavirus vaccine candidates, as China steps up its efforts in the global race.
Serbia and Pakistan have agreed to participate in the Phase 3 trials of CNBG’s vaccine candidates while Sinovac has received approval from Turkey and Bangladesh. The two companies are seeking more data from overseas as new cases in China are dwindling.”
Read the full article @ Reuters:
China’s CNBG, Sinovac find more countries to test coronavirus vaccines
China National Biotec Group (CNBG) and Sinovac Biotech Ltd said on Saturday they have each found two more countries to run late-stage clinical tests of their coronavirus vaccine candidates, as China steps up its efforts in the global race.
Hengrui Medicine sets up clinical research and development in Basel | BaselArea
“The Chinese life sciences company Hengrui Medicine is establishing a Swiss subsidiary in Basel. The European hub for clinical research and development will help the company to advance its innovative drugs, including cancer treatments.”
Read the full article @ BaselArea:
Hengrui Medicine sets up clinical research and development in Basel – Basel Area Business & Innovation
The Chinese life sciences company Hengrui Medicine is establishing a Swiss subsidiary in Basel. The European hub for clinical research and development will help the company to advance its innovative drugs, including cancer treatments.
China’s sovereign digital currency plans must be globally compatible to internationalise the yuan, analysts say | SCMP
“The ‘interoperability’ of the digital yuan with international payment systems and other central bank digital currencies will determine its use abroad.
There is a sense of urgency to promote greater use of the yuan to help China offset threat of worst-case US sanctions that could cut it off from dollar payment system.”
Read the full article @ SCMP:
China’s digital yuan ecosystem must be made to work globally, analysts say
China is set to expand the testing of its new sovereign digital currency later this year or in early 2021, but analysts say the design of its technological platform needs to be made compatible with those of other countries if the digital yuan is to play a role in international transactions.